中新网10月30日电  中国官方将进一步加强药品安全信用体系建设工作，加强失信行为的联合惩戒。失信的药品生产经营企业将被纳入“黑名单”。

Beijing, oct. 30  China's official will further strengthen the drug safety credit system construction work,Strengthen discreditable behavior of joint discipline.Dishonest drug production management enterprise will be included in the"blacklist".

　　据国家发展和改革委员会网站消息，发展改革委、人民银行等七部委日前联合印发实施了《关于进一步加强药品安全信用体系建设工作的指导意见》。发展改革委有关机构负责人就相关问题接受记者采访时指出，要建立“黑名单”制度，在各级新闻媒体和网站上进行披露和曝光。

According to the national development and reform commission website news,Development and reform commission/The people's bank has seven ministries jointly issued by the implementation[On further strengthening drug safety credit system construction work instruction opinion].Development and reform commission the relevant authorities to the related problems when accepting a reporter to interview pointed out,To establish"blacklist"system,At all levels in the news media and website for disclosure and exposure.

　　多年来，药品安全领域一直存在不同程度的诚信缺失问题，尤其是毒胶囊事件曝光后，社会对药品安全问题的反响十分强烈。

For many years,Drug safety fields have been there exists different degree of lack of credibility,Especially poison capsule events after exposure,Society for drug safety problem is very strong repercussions.

　　发展改革委有关机构负责人表示，药品安全事关人民群众切身利益、经济健康发展和社会和谐稳定。考虑到诚信缺失是导致药品领域安全问题产生的主要因素之一，且药品安全信用体系建设又是一项复杂的系统性工程，为更加全面、更加系统地推动解决药品安全领域诚信缺失问题，保障人民群众用药安全有效，联合印发了《指导意见》。

Development and reform commission said the relevant authorities,Drug safety is the vital interests of the people/The healthy development of the economy and social harmony and stability.Considering the lack of trust is lead to drug field safety problems is one of the main factors,And drug safety credit system construction is a complex systematic engineering,For a more comprehensive/More system to promote solve the lack of credibility of drug safety field,Protecting the people's drug is safe and effective,Jointly issued by the[Guiding opinions].

　　该负责人称，将启动该领域的征信工作，初步建立药品生产经营企业信用档案。从长期看，要在各部门建立完善行业信用信息记录及数据库，各地方形成统一公共信用信息平台，且实现行业内、地区内公共信用信息互联互通的基础上，推动建立更新及时、覆盖全面的药品生产经营企业信用档案。

The officials say,Will start the field of reference work,Initially established a drug production management enterprise credit files.In the long run,In every department to set up perfect industry credit information record and database,The local form a unified public credit information platform,In the industry and realize/In the area of public credit information on the basis of interconnection and interflow,Promote the establishment of updated timely/Comprehensive coverage of drug production management enterprise credit files.

　　该负责人表示，失信联合惩戒作为药品安全信用体系建设的重要方面，主要有四个方面的考虑：

This person in charge said,Dishonest joint discipline as drug safety credit system construction of the important aspect,There are four main considerations:

　　第一，各部门在现有行政处罚措施的基础上，结合监管对象的失信类别和程度，进一步明确对失信行为的行政处罚措施。在此基础上，由各部门依据药品生产经营企业失信记录，对失信主体实施行政监管性联合惩戒。

The first,Each department in the existing administrative punishment on the basis of the measures,Combined with supervision object faithless category and degree,To further clear discreditable behavior of the administrative punishment.On the basis of,By various departments according to the drug production management enterprise break faith record,To break faith subject to implement administrative supervision sex joint discipline.

　　第二，由药品行业协会对失信会员实施行业性惩戒。

The second,The pharmaceutical industry association member to break faith implementation trade retribution.

　　第三，建立“黑名单”制度，在各级新闻媒体和网站上进行披露和曝光。通过失信信息的广泛传播，使失信的药品生产经营企业受到市场性惩戒(市场交易、融资等)和社会性惩戒(社会谴责等)。

The third,To establish"blacklist"system,At all levels in the news media and website for disclosure and exposure.Through the dishonest information spread widely,That dishonest drug production management enterprise is marketability retribution(Market transaction/financing)And social discipline(Condemnation, etc).

　　第四，对药品安全领域的违法失信行为，由司法部门依法追究民事或刑事责任。

The fourth,In the field of drug safety for illegal discreditable behavior,The judicial department shall be investigated for civil or criminal liability.